AquaBounty: FDA could approve biotech salmon this year

04/24/2013 | Hartford Courant (Conn.), The

AquaBounty Technologies expects its biotech salmon, which grows twice as fast as traditional salmon, to be approved by the FDA before the year ends. "There have been no new legal issues, no new regulatory issues, no new environmental issues raised," CEO Ronald Stotish said at the BIO International Convention. The public comment period ends on Friday, and the FDA's decision could come 150 to 180 days later, Stotish said.

View Full Article in:

Hartford Courant (Conn.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID